Business
Apogee Therapeutics Provides Pipeline Progress and Reports First Quarter 2026 Financial Results
Zumilokibart advancing across multiple indications, with Phase 3 initiation in atopic dermatitis (AD) expected later this year:- APEX Phase 2 Part A 52-week data demonstrated durable maintenance and improved efficacy over time with every 3- and 6-month dosing in moderate-to-severe AD- APEX Phase 2 Part B 16-week data in AD expected in Q2 2026- Following positive Phase 1b asthma results earlier this year, expansion plans are underway with additional trial details for asthma and eosinophilic esoph
About this update from Apogee Therapeutics, Inc.
[{"type":"image","alt":"Apogee Therapeutics","displaySize":"","headline":null,"caption":"Apogee Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":84,"url":"https://media.zenfs.com/en/globenewswire.com/631e8ba0ee15d045351b6664da548326"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/U5TyEiJkPScgY1UNP1ZKtQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExOA--/https://media.zenfs.com/en/globenewswire.com/631e8ba0ee15d045351b6664da548326","width":300,"height":84},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/U5TyEiJkPScgY1UNP1ZKtQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExOA--/https://media.zenfs.com/en/globenewswire.com/631e8ba0ee15d045351b6664da548326","width":300,"height":84}},"lazy":false},{"type":"text","content":"Zumilokibart advancing across multiple indications, with Phase 3 initiation in atopic dermatitis (AD) expected later this year:- APEX Phase 2 Part A 52-week data demonstrated durable maintenance and improved efficacy over time with every 3- and 6-month dosing in moderate-to-severe AD- APEX Phase 2 Part B 16-week data in AD expected in Q2 2026- Following positive Phase 1b asthma results earlier this year, expansion plans are underway with additional trial details for asthma and eosinophilic esophagitis (EoE) expected later this year","length":540,"tagName":"p"},{"type":"text","content":"Strong cash position of $1.3B following successful public equity offering extending runway into 2029, through planned BLA filing for AD, subject to regulatory alignment","length":168,"tagName":"p"},{"type":"text","content":"SAN FRANCISCO and BOSTON, May 11, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today provided pipeline progress and reported first quarter 2026 financial results.","length":368,"tagName":"p"},{"type":"text","content":"“We are off to a rapid start in 2026, reflecting the team’s relentless focus on execution. Most notably, the APEX Phase 2 Part A 52-week results exceeded our expectations and reinforced the potentially best-in-class profile of zumilokibart as well as the central role of IL-13 as the master cytokine in AD. Zumilokibart demonstrated durable maintenance of response with 3- and 6-month ...